Press Releases

SAN FRANCISCO, Dec. 4, 2009 (GLOBE NEWSWIRE) -- LookSmart (Nasdaq: LOOK), the search advertising network and management company, today announced that CEO and President, Ted West, will speak at Search Engine Strategies Chicago Conference and Exposition on Monday, December 7th. Ted West was selected by SES Chicago's advisory board to participate on the panel, "The Quest for Perfect Information: How Network Intelligence is Transforming Search."

What:

Programmed by SearchEngineWatch.com and Incisive Interactive Marketing LLC, the Search Engine Strategies Chicago conference and exposition will feature thought-provoking speakers and outline the tools and approaches companies can employ in their search engine marketing strategies.

During "The Quest for Perfect Information: How Network Intelligence is Transforming Search," West and other panelists will come together in a meaningful forum to discuss the rapid evolution and future of search engine marketing. This panel will provide insight into how search networks are amassing data and tools to enable automated, optimized ad buying and selling decisions. Attendees will learn specific ways to improve ad-matching decisions and advertiser ROI.

 Moderator:
   * Ken Miller, CEO, Anchor Intelligence
 Speakers:
   * Stephen Scarr, Co-Found & CEO, Info.com
   * Bill Leake, President and CEO, Apogee Search
   * Ted West, CEO and President, LookSmart
   * Craig Greenfield, VP Search and Performance Media, Performics

 When:
 Monday, December 7, 2009 from 3:15 p.m. - 4:15 p.m. CST

 Where:
 The Hilton Chicago, Chicago, IL
 720 South Michigan Avenue
 Chicago, IL 60605

About LookSmart:

LookSmart (Nasdaq: LOOK) is a premier search advertising network and management company. A trusted provider of quality search advertising products and services to advertisers, LookSmart offers targeted pay-per-click search and contextual advertising via its proven Search Advertising Network. Dedicated to the quality of PPC search advertising, LookSmart is one of the five founding members of the IAB Click Measurement Panel. For more information call (888) 403-5665.

NOTE: "LookSmart" is a trademark of LookSmart, Ltd., and/or its subsidiaries in the U.S. and other countries. All other trademarks mentioned are the property of their respective owners.

CONTACT:  Horn Group Inc. for LookSmart, Ltd.
          Mandy Kakavas
          415-905-4015
          mandy.kakavas@horngroup.com

DALLAS, Dec. 4 /PRNewswire-FirstCall/ -- Newspaper publisher A. H. Belo Corporation (NYSE: AHC) said today that the Company and its bank syndicate have mutually agreed to amend the Company's revolving credit facility effective December 3, 2009.

The amendment extends the credit facility's maturity date to September 30, 2012, reduces the facility size to $25 million and releases certain real property securing the facility. The amended facility remains subject to a borrowing base. If borrowing capacity under the amended facility is less than $17.5 million, then a fixed charge coverage ratio covenant of 1:1 will apply. Other usual and customary covenants were carried forward.

"As of December 3, A. H. Belo had no borrowings under its revolving credit facility," said Robert W. Decherd, chairman, president and Chief Executive Officer. "The amended facility allows A. H. Belo to focus on managing its business and provides the financial flexibility we need going forward. A. H. Belo will continue to emphasize revenue initiatives, expense management and maximizing cash from operations."

About A. H. Belo Corporation

A. H. Belo Corporation (NYSE: AHC), headquartered in Dallas, Texas, is a distinguished newspaper publishing and local news and information company that owns and operates four daily newspapers and a diverse group of Web sites. A. H. Belo publishes The Dallas Morning News, Texas' leading newspaper and winner of eight Pulitzer Prizes since 1986; The Providence Journal, the oldest continuously-published daily newspaper in the U.S. and winner of four Pulitzer Prizes; The Press-Enterprise (Riverside, CA), serving southern California's Inland Empire region and winner of one Pulitzer Prize; and the Denton Record-Chronicle. The Company publishes various specialty publications targeting niche audiences, and its partnerships and/or investments include the Yahoo! Newspaper Consortium and Classified Ventures, owner of cars.com. A. H. Belo also owns direct mail and commercial printing businesses. Additional information is available at www.ahbelo.com or by contacting David A. Gross, vice president/Investor Relations and Strategic Analysis, at 214-977-4810.

Statements in this communication concerning A. H. Belo Corporation's (the "Company's") business outlook or future economic performance, anticipated profitability, revenues, expenses, dividends, capital expenditures, investments, impairments, future financings, and other financial and non-financial items that are not historical facts, are "forward-looking statements" as the term is defined under applicable federal securities laws. Forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those statements.

Such risks, uncertainties and factors include, but are not limited to, changes in capital market conditions and prospects, and other factors such as changes in advertising demand and newsprint prices; newspaper circulation trends and other circulation matters, including changes in readership patterns and demography, and audits and related actions by the Audit Bureau of Circulations; challenges in achieving expense reduction goals, and on schedule, and the resulting potential effects on operations; technological changes; development of Internet commerce; industry cycles; changes in pricing or other actions by competitors and suppliers; regulatory, tax and legal changes; adoption of new accounting standards or changes in existing accounting standards by the Financial Accounting Standards Board or other accounting standard-setting bodies or authorities; the effects of Company acquisitions, dispositions, co-owned ventures, and investments; general economic conditions and changes in interest rates; significant armed conflict; and other factors beyond our control, as well as other risks described in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

SOURCE A. H. Belo Corporation

CALGARY, Dec. 4 /PRNewswire-FirstCall/ - Bankers Petroleum Ltd. ("Bankers" or the "Company") (TSX: BNK, AIM: BNK) is pleased to announce that the main terms and conditions for a petroleum agreement for Block "F" exploration acreage application have been accepted by the National Agency of Natural Resources ("AKBN"). Negotiations of a Production Sharing Agreement ("PSA") will begin immediately with an objective to submit a final draft PSA by January 2010 for necessary approvals by the Government of Albania.

Block "F" is located immediately west of Bankers Petroleum Patos Marinza oil field and covers an area of approximately 740 km(2) (185,000 acres). Excluded from the area are three gas fields operated by Albpetrol, the Albanian national oil company. The area contains several seismically defined structural and amplitude anomalies prospective for oil and natural gas.

About Bankers Petroleum Ltd.

Bankers Petroleum Ltd. is a Canadian-based oil and gas exploration and production company focused on developing large oil and gas reserves. In Albania, Bankers operates and has the full rights to develop the Patos-Marinza heavy oil field and has a 100% interest in the Kucova oil field. Bankers' shares are traded on the Toronto Stock Exchange and the AIM Market in London, England under the stock symbol BNK.

SOURCE Bankers Petroleum Ltd.

School Group Receives Donation, Homeowners Receive 15 Percent Discount

CORVALLIS, Ore.--(BUSINESS WIRE)-- SunWize Residential Power Systems, the premier solar installation division of SunWize Technologies, Inc., announced today that it exceeded the goal of its 60-day Corvallis Solar Challenge. The inaugural city-wide program ended with 17 households committing to purchase solar electric systems for a total of 61,995 watts DC.

The SunWize Solar Challenge program, in which Corvallis was the first city, catalyzes an entire city or town to achieve a significant renewable energy goal. The Corvallis Solar Challenge set an objective of signing up enough residential solar systems to reach 60,000 watts in 60 days. The 60,000 watts of clean energy generating capacity is equivalent to avoided emissions of over 78,000 lbs. of CO2 every year. Participating households received the maximum 15 percent discount off the price of their systems. In addition to the 17 homeowners, T. Gerding Construction Co., a long-time Corvallis business, chose SunWize to install a 30 kW commercial system on their new LEED certified headquarters.

As part of reaching the goal in the Corvallis Solar Challenge, SunWize will donate $6,000 ($1,000 for each 10,000 watts) to the Corvallis High School Green Club toward the club's initiative to install 100 kW of solar power on the school. SunWize will present a voucher to the Green Club at a school assembly on Friday, December 4, at 10:45 a.m. PST.

"The SunWize Solar Challenge made it affordable for me to go solar. It enabled me to make the investment I always wanted to make in reducing my carbon footprint for the next generation," said Julie Williams, teacher at Corvallis High School.

"We are extremely pleased with the response to our first city-wide Solar Challenge," said David Kaltsas, Executive Vice President at SunWize. "It clearly shows that a community will come together knowing they will be making a significant contribution to their local school and the environment while receiving a considerable discount on their solar electric system."

To learn more about the Corvallis Solar Challenge or to bring the SunWize Solar Challenge to your town or city, please visit: http://www.sunwize.com/Corvallis or call (866) 436-7353.

SunWize Technologies, Inc., a subsidiary of Mitsui & Co. (U.S.A), Inc., offers superior solar energy solutions to homes and businesses in the U.S. and abroad. The SunWize advantage is complete commitment to the customer's satisfaction. Founded in 1992, SunWize is a pioneering solar distributor delivering top-tier products to the North American marketplace. The company manufactures a full line of best-in-class engineered solutions. In addition, SunWize continues to build on its reputation for high-quality residential, commercial, public sector, and industrial installations. The company operates manufacturing and distribution facilities on the east and west coasts and sales offices throughout the U.S. and Canada. For more information, call Matt Ziskin 408-510-5178 or visit www.sunwize.com.

    Source: SunWize Technologies, Inc.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company's Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics. The paper also will be published in the print version of this journal shortly. The paper is authored by Rudi Bao, M.D., Ph.D. et al and is entitled "Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer." The data discussed in this paper were generated prior to Curis' entry into a license agreement in August 2009 with Debiopharm Group, which has since renamed the compound Debio 0932.

"This publication provides further important preclinical data for Debio 0932 and we believe that these encouraging data contributed to Debiopharm's interest in licensing this molecule from Curis earlier this year," stated Dan Passeri, Curis' President and Chief Executive Officer. "Our research team continues to generate meaningful data for our targeted small molecule cancer drug candidates, and we are highly encouraged by their work."

Debio 0932 is a HSP90 inhibitor of the novel imidazopyridine class. The publication highlights data suggesting that this drug candidate holds promise for the treatment of non-small cell lung cancer (NSCLC) that becomes resistant to erlotinib and other epidermal growth factor receptor (EGFR) inhibitors due to various oncoprotein deregulations.

Following Curis' first publication related to this molecule in Clinical Cancer Research earlier this year, this paper focuses on Debio 0932's activities in NSCLC cell lines with primary or secondary resistance to EGFR inhibitors. The paper's authors show that Debio 0932 binds to HSP90 complex extracted from erlotinib-resistant NSCLC cells, displays potent antiproliferative activity in erlotinib-resistant NSCLC cell lines and exhibits durable inhibition of multiple oncoproteins as well as induction of apoptosis, or programmed cell death, in erlotinib-resistant NSCLC cells. Debio 0932 also potently inhibits tumor growth in subcutaneous xenograft models of NSCLC cell lines that harbor acquired and/or primary resistance to EGFR inhibitors, respectively. In addition, Debio 0932 significantly prolongs animal survival in orthotopic lung tumor models, which may be partially attributed to its preferential exposure in lung tissue. Lastly, Debio 0932 is able to extend animal survival in a brain metastatic model of an erlotinib-resistant cell line, further confirming its ability to cross the blood-brain barrier. Correlating with its effects in various tumor models, the compound induces degradation of receptor tyrosine kinases and downstream signaling molecules of the PI3K/AKT and RAF/MEK/ERK pathways simultaneously, with concurrent induction of apoptosis in vivo.

According to the American Cancer Society, lung cancer is the leading cause of cancer mortality in the United States, accounting for one-third of all cancer deaths, and therefore represents a significant unmet medical need.

About the Debiopharm Hsp90 License Agreement

In August 2009, Curis entered into a worldwide, exclusive license agreement with Debiopharm for Curis' Hsp90 technology, including CUDC-305, the company's lead Hsp90 inhibitor development candidate, which has been renamed Debio 0932. Under the agreement, Debiopharm has assumed all future development responsibility and will incur all future costs related to the licensed Hsp90 technology. Curis received a $2 million up-front license fee and expects to receive additional near-term payments, including a payment upon the acceptance of Debiopharm's application to begin Phase I clinical trials of Debio 0932 and upon treatment of the fifth patient in the first Phase I clinical trial. The up-front and near term payments under this transaction are expected to provide Curis with capital to fund its planned operations into the second half of 2011. Curis is eligible to receive additional contingent payments assuming the successful achievement of other specified clinical development and regulatory approval objectives as well as royalties on sales, if any, of any products that are successfully commercialized by Debiopharm or its sublicensees. Curis currently expects that Debiopharm will file an application with regulatory authorities to begin Phase I clinical testing in the fourth quarter of 2009.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales in excess of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: www.debiopharm.com.

Curis Cautionary Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation the Company's statements regarding: the potential for Debio 0932 in treatment of NSCLC, its estimate that Debiopharm will file a CTA in December 2009 and the Company's estimates regarding its ability to fund its operations in the second half of 2011. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates", "will", "may" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause the actual results to be materially different from those indicated by such forward-looking statements including, among other things:

    --  Curis may experience adverse results, delays and/or failures in its
        internal drug development programs, including with respect to its Phase
        I clinical trial of CUDC-101, and with respect to its ongoing
        preclinical studies of its other targeted cancer programs.
    --  Genentech and Debiopharm may experience adverse results, delays and/or
        failures in their respective development programs under collaboration
        with Curis. For example, Genentech may not be able to replicate in later
        trials any favorable outcomes from earlier trials of GDC-0449, and
        Debiopharm may not be able to successfully advance Debio 0932 into
        clinical trials as planned.
    --  Curis may experience difficulties or delays in obtaining or maintaining
        required regulatory approvals for products under development both
        internally and through its collaborations.
    --  Curis may not be able to obtain or maintain the intellectual property
        protection necessary for the development and commercialization of drug
        candidates based on its technologies.
    --  Curis may not be able to obtain the substantial additional funding
        required to conduct research and development of its drug candidates.
    --  Curis may experience unplanned cash requirements, and may not received
        additional anticipated payments under its collaborations, any of which
        could shorten the estimated period in which Curis will have cash to fund
        its operations and which could also adversely affect Curis' estimated
        operating expenses for 2009 and beyond.
    --  Curis faces risks relating to its ability to enter into and maintain
        planned collaborations for development candidates under its targeted
        cancer programs, its ability to maintain its current collaborations with
        Genentech and Debiopharm, and the risk that any such collaborators will
        not perform adequately.
    --  Curis also faces other risk factors identified in its Annual Report on
        Form 10-K for the year ended December 31, 2008, its Quarterly Report for
        the Quarter ended September 30, 2009 and other filings that it
        periodically makes with the Securities and Exchange Commission.

In addition, any forward-looking statements represent the views only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.

    Source: Curis, Inc.